Home Technology R&D Therapeutic Area Company News Careers Contact Find us » ) Novel treatments to help patients with central nervous system disorders News archive 2016 - BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research - Update from the Annual General Meeting 2016 - US patent on Parkinson’s disease granted - Antibody-based PET imaging of amyloid beta protofibrils in the Alzheimer brain – New findings from Uppsala University in collaboration with BioArctic 2015 2014 2013 2012 2011 2010 2009 2008 2007 - BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research Download as pdf » Stockholm, Sweden, September 20, 2016 BioArctic announced that it entered into a strategically important collaboration with AbbVie (NYSE: ABBV), a global biopharmaceutical company, to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein for the treatment of Parkinson’s disease and other potential indications. Parkinson’s disease is the second most-common neurological disease, affecting more than 10 million people worldwide. Mutations in alpha-synuclein are strongly linked to development of Parkinson’s disease. Soluble aggregates of the alpha-synuclein protein are toxic to neurons and lead to the deposits that are a hallmark of the disease. “AbbVie has shown a strong commitment to Parkinson’s disease and I am proud that they have chosen to collaborate with BioArctic. I am looking forward to a successful partnership that hopefully will result in a new innovative disease modifying treatment becoming available to the large number of patients suffering from Parkinson’s disease,” said Gunilla Osswald, CEO at BioArctic. Financial terms were not disclosed. For more information, please contact Gunilla Osswald, Ph.D., CEO, BioArctic AB, gunilla.osswald@bioarctic.se phone +46-(0)8-6956933 About BioArctic BioArctic AB is a Swedish privately held research-based biopharmaceutical company founded in 2003. The company’s mission is to provide new and effective treatments for patients with disorders in the central nervous system. Its proprietary technology and dedicated personnel have made it possible to develop new immunotherapeutic approaches to neurodegenerative diseases. We focus on therapy areas with a large medical need such as Alzheimer’s disease, Parkinson’s disease and spinal cord injury. For further information on BioArctic and its research, please visit www.bioarctic.se. About AbbVie AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page. HomeLegal noticeContact © BioArctic AB, 2003-2016, BioArctic AB, Warfvinges väg 35, SE-112 51 Stockholm, SWEDEN, Phone: +46-(0)8-6956930, Fax: +46-(0)8-6956939